-+ 0.00%
-+ 0.00%
-+ 0.00%
Curocell Secures South Korean Approval to Amend Phase 1/2 Trial of CRC01 in Adult Leukemia
Share
Listen to the news
Curocell Secures South Korean Approval to Amend Phase 1/2 Trial of CRC01 in Adult Leukemia
  • Curocell received South Korean regulatory clearance on Nov. 18, 2026, to amend its CRC01 trial in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
  • The amendment separates the leukemia trial protocol following marketing authorization for relapsed or refractory diffuse large B-cell lymphoma, enabling independent trial operations.
  • The Phase 1/2 study will evaluate CRC01’s tolerability, safety and efficacy, with completion expected Sept. 30, 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curocell Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261118900627), on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending